Dr Peter A Merkel reports grants from ChemoCentryx, during the conduct of the study; grants, personal fees from AbbVie, grants, personal fees from AstraZeneca, grants, personal fees from Boehringer-Ingelheim, grants, personal fees from Bristol-Meyers Squibb, grants, personal fees from ChemoCentryx, personal fees from CSL Behring, personal fees from Dynacure, personal fees from EMD Serono, grants, personal fees from Forbius, grants, personal fees from Genentech/Roche, grants, personal fees from GSK, personal fees from Immagene, grants, personal fees from InflaRx, personal fees from Jannsen, personal fees from Kiniksa, personal fees from Kyverna, personal fees from Magenta, personal fees from MiroBio, personal fees from Mitsubishi, personal fees from Neutrolis, personal fees from Novartis, personal fees from NS Pharma, personal fees from Pfizer, personal fees from Q32, personal fees from Regeneron, personal fees from Sparrow, grants, personal fees from Takeda, grants from Eicos, grants from Electra, grants from Sanofi, personal fees from UpToDate, outside the submitted work. Dr David RW Jayne reports personal fees from ChemoCentryx, grants from Vifor, during the conduct of the study; personal fees from AstraZeneca, other from Aurinia, grants from GSK, personal fees from Takeda, personal fees from Roche, outside the submitted work. Dr Pirow Bekker reports personal fees from ChemoCentryx, outside the submitted work. The authors report no other conflicts of interest in this communication.